What does HEMB stand for?

Hemophilia B

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Hydraulic Equipment Manufacturers' Association (United Kingdom) Hydroxy Ethyl Methacrylate Hydroxyethyl Methacrylate Historical European Martial Arts Coalition Homeowners' Emergency Mortgage Assistance Program (Pennsylvania) Historical Electronics Museum Amateur Radio Club Heavy Expanded Mobility Ammunition Trailer Heavy Expanded Mobility Tactical Truck Heat & Mass Transfer Information Center Blood (Prefix)		Habersham Electric Membership Corporation (Georgia) High-Energy Metabolite Composition at Rest Holocaust Education and Memorial Centre of Toronto (Canada) Home Equity Mortgage Conversion (reverse mortgage) Home Equity Mortgage Corp. (various locations) Hydroxy Ethyl Methyl Cellulose Heavy Equipment Maintenance Company Hunt Exploration and Mining Company (various locations) Hall Effect Measurement Equipment (UK) Hemorrhage (medical)

Samples in periodicals archive:

There are three types of hemophilia - Hemophilia A, which is caused by non-functioning clotting Factor VII, is the most common; Hemophilia B is caused by non-functioning clotting Factor IX; and Hemophilia C, which is caused by non-functioning clotting Factor XI.

Hemophilia - A General Examination to the Incurable Bleeding Disease

CASE SUMMARY A 16-year-old boy with a medical history of hemophilia B presented to the emergency department with a 2-day history of left knee pain and swelling.

Bleeding diathesis with hemophilic arthropathy

Hemophilia B is characterized by deficient or defective factor IX.

BAYER EXPANDS HEMOPHILIA PORTFOLIO FEATURING MAXY-VII

Cell Genesys is pursuing gene therapies for hemophilia A and hemophilia B -- genetic deficiencies in factor VIII and factor IX clotting factor genes, respectively.

Cell Genesys obtains results from preclinical hemophilia gene therapy ...

amp; STOCKHOLM -- Biogen Idec (NASDAQ: BIIB) and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.

Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting ...

The two most common types are hemophilia A and hemophilia B.

Hemophilias - Treatments and Therapies

Hemophilia B is characterized by deficient or defective factor IX.

BAYER UNVEILS KOGENATE FS WITH BIO-SET FOR HEMOPHILIA A

Almost two years ago physicians and scientists at The Children's Hospital of Philadelphia and Stanford University Medical Center initiated a Phase I clinical trial of Coagulin-B, Avigen's gene therapy treatment for hemophilia B.

Avigen granted broad hemophilia A gene therapy patent